SEI Investments’s CytomX Therapeutics CTMX Stock Holding History

SEI Investments’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$110K	Hold	40,499	–	–	﹤0.01%	3165
2026 Q2	$152K	Sell	40,499 -207,749	-84%	-$793K	﹤0.01%	3110
2026 Q1	$1.17M	Buy	248,248 +124,124	+100%	+$630K	﹤0.01%	2285
2025 Q4	$529K	Buy	+124,124	New	+$472K	﹤0.01%	2486
2025 Q2	–	Sell	-487,902	Closed	-$310K	–	2814
2025 Q1	$310K	Hold	487,902	–	–	﹤0.01%	2328
2024 Q4	$503K	Hold	487,902	–	–	﹤0.01%	2182
2024 Q3	$576K	Buy	487,902 +105,179	+27%	+$134K	﹤0.01%	2133
2024 Q2	$467K	Buy	+382,723	New	+$762K	﹤0.01%	2181
2021 Q3	–	Sell	-64,469	Closed	-$399K	–	2573
2021 Q2	$399K	Sell	64,469 -14,310	-18%	-$111K	﹤0.01%	2205
2021 Q1	$609K	Buy	78,779 +39,463	+100%	+$312K	﹤0.01%	1943
2020 Q4	$258K	Sell	39,316 -68,456	-64%	-$489K	﹤0.01%	2274
2020 Q3	$717K	Buy	+107,772	New	+$799K	﹤0.01%	1752

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

SEI Investments's CTMX Position: Q3 2026 in Review

SEI Investments held its CytomX Therapeutics (CTMX) position steady in Q3 2026 at 40,499 shares worth $110K. The position accounts for ﹤0.01% of the portfolio, ranked #3165.

SEI Investments first reported a position in CTMX in Q3 2020 and has held it in 12 quarters since. The position peaked at $1.17M in Q1 2026. 128 funds tracked by Wall St. Rank hold CTMX as of Q3 2026.

SEI Investments held 40,499 shares of CytomX Therapeutics worth $110K as of Q3 2026.
SEI Investments left its CytomX Therapeutics share count unchanged in Q3 2026.
CytomX Therapeutics made up ﹤0.01% of SEI Investments's portfolio in Q3 2026, its #3165 holding.
SEI Investments first reported a position in CytomX Therapeutics in Q3 2020 and has held it in 12 quarters since.
SEI Investments's CytomX Therapeutics position peaked at $1.17M in Q1 2026.
128 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2026.

Based on SEI Investments's 13F filing for Q3 2026, filed 10 Nov 2026.